Equibles does not estimate personal net worth.
Get an email with a short summary when Anika Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ANIK alertsSteve Griffin is recorded as CEO and Board Member at Anika Therapeutics, Inc. (ANIK) since February 1, 2026 and CFO at Anika Therapeutics, Inc. (ANIK). Anika Therapeutics, Inc. reported in an 8-K filed January 8, 2026 that Steve Griffin was appointed Class III director, effective February 1, 2026. Anika Therapeutics, Inc. reported in an 8-K filed January 8, 2026 that Steve Griffin was appointed President and Chief Executive Officer, effective February 1, 2026. Anika Therapeutics, Inc. reported in an 8-K filed May 8, 2024 that Steve Griffin was appointed Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024. Steve Griffin has spoken on 5 earnings calls across 1 company, most recently for Anika Therapeutics, Inc. on July 29, 2026. Anika Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Anika Therapeutics, Inc. includes Cheryl Blanchard (CEO and Board Member), Stephen (Steve) Griffin (CEO and Board Member), Stephen D. Griffin (CEO, CFO and Board Member) and 7 others.
“On January 7, 2026, upon the recommendation of its Governance and Nominating Committee, the Board appointed Steve Griffin to join the Board, effective as of February 1, 2026.”
“Steve Griffin, currently serving as Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed by the Board to serve as the Company's President and Chief Executive Officer, effective as of February 1, 2026.”
“These results reflect execution against the three strategic priorities I highlighted in my first earnings call in February. Accelerating sustainable revenue growth, driving operational excellence across the organization, and advancing our hyaluronic acid-based innovation pipeline.”
“In the first quarter of 2026, we made meaningful progress across Annika's three strategic priorities, driving sustainable commercial channel growth, advancing our hyaluronic acid-based innovation pipeline, and strengthening execution across our organization our first quarter performance reflects a more focused…”
“Let's first start with the updates in the quarter. Please refer to Slide 4 of the presentation. In the first quarter, Anika generated $26.2 million in total revenue, down 10% versus the same period in 2024.”
“Before I review the quarter, I'll start by providing some further details regarding the recently announced sale of the Parcus business.”
“Before I review the quarter, I'll briefly discuss the Arthrosurface transaction.”
2026-02-01–present
2026-02-01–present
Drug Manufacturers - Specialty & Generic · Healthcare
CFO, CEO, Board Member
2026-02-01–present
